FDA says potential for additional doses in Pfizer COVID-19 vaccine vials
The Food and Drug Administration Center for Biologics Evaluation and Research Prevention has addressed new information that shipped vials of Pfizer’s BND162b2 mRNA COVID-19 vaccine contain extra doses, indicating that it is acceptable to use every full dose obtainable from each product vial.
Read yesterday’s AHA Special Bulletin for more details.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…